Tildipirosin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tildipirosin: From Veterinary Respiratory Infection to Leprosy (Predicted)
One-Sentence Summary
Tildipirosin is a 16-membered macrolide antibiotic developed exclusively for veterinary use (respiratory disease in cattle and swine); it has never been approved or dosed in humans and holds no marketing authorisation in Denmark. The TxGNN model predicts a possible link to Leprosy, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests entirely on structural analogy to other macrolides.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not applicable — veterinary antibacterial only (respiratory infections in cattle/swine); no human-approved indication exists |
| Predicted New Indication | Leprosy |
| TxGNN Prediction Score | 99.01% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for Tildipirosin is not available (flagged as a Blocking/High-severity data gap in the source pack). Based on known structural information, Tildipirosin is a 16-membered ring macrolide closely related to tilmicosin and tulathromycin, presumed — by analogy to this drug class — to bind the bacterial 50S ribosomal subunit and inhibit protein synthesis. It has no recorded use, dosing, or pharmacokinetic/toxicology data in humans.
The link to leprosy is not entirely without pharmacological precedent: certain human macrolides (e.g., clarithromycin) do have established clinical activity against Mycobacterium leprae, and share the same general ribosomal binding mechanism. However, this is an analogy drawn from other members of the macrolide class, not from any direct evidence involving Tildipirosin itself.
Because Tildipirosin has never been administered to humans, its applicability to leprosy cannot currently be assessed beyond this class-level mechanistic analogy. The absence of any human PK/PD, safety, or efficacy data represents a fundamental translational gap that must be resolved before this candidate can be meaningfully evaluated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Tildipirosin holds no marketing authorisation in Denmark (0 licenses on record) and is not registered for human use. It is authorised in the EU only as a veterinary product (e.g., under the brand Zuprevo) for treatment of bovine and swine respiratory disease.
Safety Considerations
No human safety data exist for Tildipirosin — key warnings, contraindications, and drug interaction data are all unavailable, and no Summary of Product Characteristics (SmPC) for human use exists because the product is not authorised for human administration. Safety must be established from first principles (nonclinical toxicology, first-in-human studies) rather than inferred from existing labeling.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-derived only (L5, decision stage S0), with zero supporting clinical trials or literature, no human mechanism-of-action data, and no history of human administration for this veterinary-only compound. The gap between current evidence and a viable repurposing candidate is too large to proceed.
To proceed, the following is needed:
- Confirmed mechanism of action and any available nonclinical pharmacology/toxicology data (DrugBank/EMA veterinary assessment reports)
- Evidence that Tildipirosin (not just other macrolides) has antimycobacterial activity against M. leprae
- A first-in-human safety/tolerability pathway, since no human dosing data exist
- Ongoing monitoring for clinical trials or published literature on this drug-disease pair
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.